"Nowadays, everybody is thinking about this and how we can have better products for the patients, and there are a lot of discussions about personalized medicine. There are a lot of advances in this area, that is quite a new area, but we see that the development and the industry will grow in this direction, and here in Latin America there are a lot of companies, there are a lot of people thinking about this. It's of course a priority for the government, but also a challenge for the government and for the society."
Eduardo Emrich, president and CEO of Biominas Brasil, speaking at the BIO Latin America Conference

"PD-1 and PD-L1 antibodies are clinically proven for their efficacy, but overall only around 20% of the patients are able to benefit from them. We do not focus on PD-1/PD-L1 monotherapies. There are too many similar programs in this space. Instead, we will develop bispecifics and multispecifics that target different checkpoints, including PD-1 and PD-L1. They are believed to be more efficacious and able to create synergy."
Xiaolin Liu, CEO of Biotheus Inc., a Chinese startup

"We are predicting a 27% decline in total funding into the U.S. and Europe biopharma in 2019."
Katherine Andersen, head of life science and health care relationship banking at Silicon Valley Bank, on the impact on biopharmaceutical investments this year from the ongoing trade war between the U.S. and China

No Comments